DATE: November 14, 2017
TIME: 09:00am PST, 12:00pm EST
The CRISPR-Cas9 system has been adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming this CRISPR activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. This exciting complement to loss-of-function studies (such as with RNAi and CRISPR-Cas9) also provides new tools to identify gene functions that might otherwise go undetected using a downregulation or knockout mechanism alone.
With CRISPRa, the guide RNAs form a complex with a nuclease-deactivated Cas9 (dCas9) which is in turn fused to transcriptional activators. This machinery then acts at the transcription start sites to upregulate expression of a target gene. In this webinar, we will describe different CRISPRa technologies and provide experimental considerations for using either synthetic guide RNA (crRNA:tracrRNA) or lentiviral sgRNA, in either arrayed or pooled screening formats. These platforms can be applied in tandem to enable both rapid follow-up of screen hits and development of complementary assays for functional gene analysis.
In this webinar you will learn:
Molecular Biology
Cell Biology
Cancer Research
Biotechnology
Genetics
Gene Expression
Cell Culture
Biochemistry
Crispr-Cas9
Genomics
Molecular Diagnostics
Immunology
Pcr/rt-Pcr/real-Time Pcr
Biomarkers
Dna
North America50%
Europe29%
Asia8%
South America4%
Oceania2%
Africa2%
Website Visitors100%
Research Scientist20%
Student18%
Post Doc14%
Scientist12%
Educator/Faculty11%
Executive7%
Facility/Department Manager5%
Medical Doctor/Specialist5%
Lab Management3%
Medical Laboratory Technician2%
Marketing/Sales1%
Clinical Laboratory Scientist1%
Biologist1%
Academic Institution16%
Research Institute8%
Biotech Company5%
Hospital2%
Government2%
Medical School2%
Clinical Laboratory2%
Pharmaceutical Company1%
Life Science Company1%
Ambulatory Care1%
Medical Center1%
Non-Profit Organization1%
Consultant1%
Industrial Company1%
Other3%